Skip to search formSkip to main contentSkip to account menu

LY2439821

Known as: LY-2439821 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ixekizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AB0229 Does Serum Level of IL-17 Affect Disease Activity and Functional Disability in Rheumatoid Arthritis Patients? Relation between Serum IL-17 Level, DAS-28 and HAQ-DI
Background Rheumatoid arthritis (RA) is a chronic, progressive, systemic inflammatory disease. Interleukin-17 (IL-17) is a… 
2013
2013
OP0021 A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: Naïve to biologic therapy or…
Background IL-17A (IL-17) is a potential therapeutic target for rheumatoid arthritis (RA) therapy. Objectives To evaluate an anti… 
2012
2012
Naive to Biologic Therapy or Inadequate Responders to TNF- Inhibitors: A Phase 2 Study of LY2439821
Review
2010
Review
2010
Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
Th17 cells play crucial roles not only in host defense but also in many human autoimmune diseases and corresponding animal models… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)